Option Care Health (OPCH) Reports Earnings Tomorrow: What To Expect

Alternate site health provider Option Care Health (NASDAQ:OPCH) will be reporting results this Tuesday before the bell. Here’s what you need to know.

Option Care Health beat analysts’ revenue expectations last quarter, reporting revenues of $1.44 billion, up 12.2% year on year. It was a mixed quarter for the company, with a narrow beat of analysts’ revenue estimates but full-year EPS guidance in line with analysts’ estimates.

Is Option Care Health a buy or sell going into earnings?

This quarter, the market is expecting Option Care Health’s revenue to grow 8.6% year on year, slowing from the 19.7% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Option Care Health has a history of exceeding Wall Street’s expectations.

Looking at Option Care Health’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Brookdale’s revenues decreased 3.4% year on year, missing analysts’ expectations by 1.7%, and Guardant Health reported revenues up 39.4%, topping estimates by 3.5%. Brookdale traded down 9.7% following the results while Guardant Health was also down 3.1%.

Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.4% on average over the last month. Option Care Health is down 1.4% during the same time and is heading into earnings with an average analyst price target of $39.82 (compared to the current share price of $35.69).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares.